Intellia Corp (NTLA) Company Cash Funds

Intellia Corp - graphic logo of issuer NTLA

R&D pipeline dynamics drove the year's volatility, and the cash reserves on GURU.Markets reflect this momentum, where 0.48 shows the value of this parameter. The financial stability of Intellia Therapeutics (NTLA) is based on the commercialization of CRISPR drugs against ATTR, however, costly cryogenic transportation of biomaterials requires significant expenditures, making liquidity monitoring critical for the biotech startup's survival.

NTLA - Intellia Corp Company Cash Reserve over the range 07/04/2022 - 11/21/2026

Comprehensive metric breakdowns and analytics for Intellia Therapeutics, Inc. (NTLA)

- market capitalization details:
- cash availability and cash flow indicators:
Basic company analysis:intelliatx.com
Product sample of intelliatx.com

A stable liquidity reserve is critical for assessing the viability of the biotech sector, as it determines the funding horizon until product commercialization. By analyzing the current cash position, an investor tracks the absolute volume of funds to hedge against bankruptcy, which for Intellia Therapeutics (NTLA) ensures the development of proprietary CRISPR technologies and the protection of patent barriers during costly clinical trials.

Competitors of Intellia Therapeutics

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Stoke - Company Cash on Hand|BLFS: Company Cash and Cash Equivalents|Wave Life Sciences Corp - Company Cash Volume|Maze Therapeutics, Inc. (MAZE) - Company Cash on Hand|Sionna Therapeutics Inc (SION) - Company Cash Funds|Company Cash on Hand Prime Medicine Corp|Company Cash Funds tayshagtx.com|QURE - Company Cash Position|Company Cash on Hand MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Company Cash Position|Company Cash Volume SLDB (Solid Biosciences Inc.)|Company Cash Balance OCGN|PacBio Corp - Company Cash Volume|Benitec Biopharma Inc. (BNTC) - Company Cash on Hand|DSGN: Company Cash Volume|Company Cash and Cash Equivalents RCKT|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume